APPROVED: Bayer's Adempas gains FDA OK in PAH/CTEPH
This article was originally published in Scrip
Executive Summary
Bayer Healthcare gained the FDA's nod on 8 October to market riociguat under the brand name Adempas as the first and only drug approved in the US to treat two rare forms of pulmonary hypertension: pulmonary arterial hypertension (PAH), or WHO Group 1, and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), or WHO Group 4.